Wells Fargo Remains a Buy on Ionis Pharmaceuticals (IONS)

In a report released yesterday, Jim Birchenough from Wells Fargo maintained a Buy rating on Ionis Pharmaceuticals (IONSResearch Report). The company’s shares closed last Monday at $64.61.

According to TipRanks.com, Birchenough is a 5-star analyst with an average return of 21.4% and a 51.0% success rate. Birchenough covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Crispr Therapeutics AG, and Akcea Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Ionis Pharmaceuticals with a $67.33 average price target.

See today’s analyst top recommended stocks >>

Ionis Pharmaceuticals’ market cap is currently $9.09B and has a P/E ratio of 21.54. The company has a Price to Book ratio of 6.80.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs.